2 unknown. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
Follow PHI-101: new trials by email Literature Review of PHI-101 trials Research Report on PHI-101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) PHI-101 administration - Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma | Phase 1 | Unknown | Seoul National University Hospital | 36 | 2020-12-17 | 2023-06-26 |
| Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML PHI-101 - Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Unknown | Seoul National University Hospital | 42 | 2020-06-08 | 2021-04-20 |
Leukemia, Myeloid, Acute (1) · Recurrence (1)
Seoul National University Hospital (2)
South Korea (2)
Hee Seung Kim, MD (1) · Sung-Soo Yoon, MD. PhD (1)